After finishing his PhD, he joined the laboratories of Transgene, a biotechnology company, where he started his career as a researcher in molecular biology.
He then became in charge of the Quality Assurance, before participating to the design and implementation of the production and Quality Control and manufacturing unit for gene transfer vectors intended for clinical use. When appointed Transgene’s Vice President of pharmaceutical and industrial operations, he joined the board of directors with whom he shared the pending projects and responsibilities until he left to set up PharminCell, in September 2011.
This career path gave him the opportunity to face and analyze complex situations in an ever-changing operational context and in a regulatory framework that needed to be constantly interpreted. Rémi Gloeckler had to deal with many different fields: from the lab bench to the production areas, from the confined production of genetically modified organisms to the establishment of specifications and norms, and from the regulatory process to the management of interactions prior to the implementation of clinical trials. He managed to provide innovation to all these aspects via a reflection process, carried out as much with the internal staff as with the supervisory authorities.
This unique experience of the pharmaceutical world and more precisely of the development of these innovative therapeutic means gave him the opportunity to meet many companies focused on very specific fields of the pharmaceutical industry. In the majority of cases, these meetings have led to the setting up of audits and inspections in France and abroad.
During his professional experience, Rémi Gloeckler also delivered many presentations within international conferences and congresses, during which he managed to build up a large network of contacts. He also conducts scheduled interventions in schools and academic trainings.
This experience, doubled with the experience of experts gathered within the PCS network, enables PharminCell PCS-France to act as a trustworthy partner with major intervention capacities, and thus to cover all the development and drug production stages, and more particularly the innovative drugs.